Autonomix Medical, Inc.
No enriched coverage for $AMIX in the last 7 days.
No SEC Form 4 filings for $AMIX in the last 30 days.
This article details the pre-market movements of 12 health care stocks, highlighting both gainers and losers. SenesTech, Sensei Biotherapeutics, and SELLAS Life Sciences Group are among the top gainers, while Outlook Therapeutics, Intelligent Bio Solutions, and Autonomix Medical lead the losers. The report provides their respective stock changes and market capitalizations.
Autonomix Medical, Inc. has been granted a European patent (EP4230133) for its platform technology involving systems, devices, and methods for precise, feedback-driven neuromodulation and denervation of cardiac tissues. This patent significantly strengthens the company's global intellectual property portfolio for nerve-targeted therapies in cardiology, including applications in hypertension, arrhythmia, and heart failure. The technology aims to provide precision treatments by sensing and mapping autonomic/cardiac signals.
Autonomix Medical (NASDAQ: AMIX) has been granted a European patent for its cardiac therapy platform, EP4230133, which covers systems and methods for precise, feedback-driven neuromodulation and denervation for cardiac tissues. This patent complements a U.S. patent and expands its intellectual property portfolio to address tough diseases like arrhythmias, heart failure, and hypertension. The news led to a significant positive market reaction for AMIX stock, with a 55.27% gain and heavy trading volume.
